

Joint modelling of longitudinal biomarkers for survival prediction: an application using clinical trial data

Louise Linsell, Yuxian Chen, Barbara Torlinska, Keith Abrams


Funded by Bayer Pharmaceuticals

Clinical trial data

- We used an integrated dataset of 3 early phase trials (*data-cut 20 July 2021*) which investigated the performance of Larotrectinib as a targeted cancer therapy¹:
 - > Phase I adult dose-escalation study [20288]
 - > Phase II adolescent & adult basket trial [NAVIGATE]
 - > Phase I/II paediatric trial [SCOUT]
- Larotrectinib is an EMA and FDA approved treatment for patients with solid tumours and positive for a *NTRK* gene fusion.
- Early results have shown that larotrectinib is effective at shrinking tumours and preventing progression across a range of tumour types.

¹ Hong DS, Dubois SG, Kummar S et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncology* 2020; 21(4): 531-540

Clinical trial data





- Kaplan- Meier survival estimate for the integrated dataset of 3 trials (data-cut 20 July 2021)
- Included 196 patients with non-primary CNS tumours treated with Larotrectinib
- At 5 years follow-up, median overall survival has not been reached

Number of mortality events by tumour type

	Number (%) of mortality events (n=196)
Site of primary tumour:	
Soft tissue sarcoma	13/65 (20.0)
Lung	5/23 (21.7)
Salivary gland	6/25 (24.0)
Thyroid	9/30 (30.0)
Other	25/53 (47.2)
Total	58/196 (29.6)

Intermediate biomarker: Sum of diameters of target lesions (mm)

Patient trajectories



— Lowess smoothing

Joint model specification

- Bayesian joint model (fitted using MCMC in JAGS):
 - Repeated measures linear regression submodel for tumour burden biomarker
 - Weibull submodel for overall survival
- Submodels linked by an association parameter:
 - Absolute (current) value
 - Change from baseline (slope association)

MCMC: Markov chain Monte Carlo, JAGS: Just Another Gibbs Sampler

Joint model specification

- 3 joint models were fitted with different assumptions about the association parameter in relation to tumour type:
 - > **Common** (one association parameter for all tumour types)
 - > **Exchangeable** (tumour-specific association parameters, “borrows strength”)
 - > **Independent** (tumour-specific association parameters, hierarchical)
- Patient-specific predictions of overall survival were then extrapolated from the joint models
- Compared to predictions from a standard parametric Weibull model.

Association parameters between tumour burden and overall survival for the 3 joint models

Model	Tumour type	Events/patients	Association hazard ratio	95% Credible interval
Common	All tumours	58/196	1.09	1.05 to 1.14
Exchangeable	Soft tissue sarcoma	13/65	1.10	1.00 to 1.22
	Lung	5/23	1.08	1.00 to 1.18
	Salivary gland	6/25	1.05	0.83 to 1.18
	Thyroid	9/30	1.01	1.03 to 1.20
	Other	25/53	1.08	1.03 to 1.14
Independent	Soft tissue sarcoma	13/65	1.12	0.94 to 1.27
	Lung	5/23	1.08	0.87 to 1.23
	Salivary gland	6/25	0.78	0.59 to 1.09
	Thyroid	9/30	1.15	1.03 to 1.27
	Other	25/53	1.08	1.02 to 1.14

- Association HR is the increase in the risk of mortality per 10mm increase in tumour burden

Extrapolated survival results from the 3 joint models and a Weibull proportional hazards (PH) model



Model	Restricted mean survival time (years), 95% CrI	Median (years), 95% CrI	Landmark survival at 10 years (%), 95% CrI	Model fit (DIC)
Weibull PH	8.04 (4.88 to 13.44)	4.91 (3.25 to 6.57)	27.7 (13.7 to 39.8)	-
Common	8.46 (5.11 to 13.84)	4.54 (3.46 to 5.96)	27.6 (16.3 to 38.8)	16265
Exchangeable	8.88 (5.59 to 14.58)	4.58 (3.57 to 5.98)	28.1 (17.3 to 38.3)	15974
Independent	12.08 (7.22 to 17.80)	4.89 (3.70 to 6.40)	32.7 (21.43 to 40.31)	16018

- N=196 patients, 58 events
- Current value association structure linking tumour biomarker to overall survival

PH: proportional hazards, CrI: credible interval, DIC: deviance information criteria

Tumour-specific survival predictions – Joint Model (exchangeable)

Soft tissue sarcoma



Joint Modelling: potential benefits

- Estimate biomarker trajectories, adjusting for informative drop-out
- Estimate the association between survival and the biomarker, accounting for uncertainty in the biomarker trajectory
- Provide patient-specific survival predictions based on biomarker profiles up to the time of censoring
- Hierarchical modelling can be used for clustered data to provide subgroup-specific estimates of the association parameter and overall survival
- Can fit more than one biomarker/time-to-event outcome simultaneously in a multivariate joint model, with the correlation structure between them modelled appropriately

Joint Modelling: potential downfalls

- More complicated to fit than standard parametric models
- Exchangeable models can be sensitive to the choice of prior distribution, when there is a lack of information within each subgroup
- Hierarchical modelling requires adequate numbers of patients/events within each cluster/subgroup

Acknowledgements

Authors

- Louise Linsell, DPhil MSc BSc, louise.linsell@visibleanalytics.co.uk, Visible Analytics, Oxford, UK.
- Noman Paracha, MSc BSc, Bayer Pharmaceuticals, Basel, Switzerland.
- Jamie Grossman, PhD MBA BA, Bayer Pharmaceuticals, Ohio, USA.
- Carsten Bokemeyer, MD, University Medical Centre Hamburg Eppendorf, Hamburg, Germany.
- Jesus Garcia-Foncillas, MD PhD, University Cancer Institute & the Department of Oncology, Autonomous University, Madrid, Spain.
- Antoine Italiano, MD PhD, Institut Bergonié, Bordeaux, France.
- Gilles Vassal, MD PhD, Gustave Roussy Comprehensive Cancer Center, Villejuif, France.
- Yuxian Chen, MSc BSc, Visible Analytics, Oxford, UK.
- Barbara Torlinska, PhD MSc MA, Visible Analytics, Oxford, UK.
- Keith Abrams, PhD MSc BSc, Department of Statistics, University of Warwick, UK.